Fertility and Sterility
Volume 91, Issue 6 , Pages 2445-2450 , June 2009

Matched-samples comparison of intramuscular versus vaginal progesterone for luteal phase support after in vitro fertilization and embryo transfer

  • Naveed Khan, M.D.

      Affiliations

    • Shady Grove Fertility Reproductive Science Center, Rockville, Maryland
    • ,
  • Kevin S. Richter, Ph.D.

      Affiliations

    • Shady Grove Fertility Reproductive Science Center, Rockville, Maryland
    • Corresponding Author InformationReprint requests: Kevin S. Richter, Ph.D., Shady Grove Fertility Reproductive Science Center, 15001 Shady Grove Road, Suite 400, Rockville, Maryland 20850 (FAX: 301-340-7503).
    • ,
  • Tasha L. Newsome

      Affiliations

    • Shady Grove Fertility Reproductive Science Center, Rockville, Maryland
    • ,
  • Emily J. Blake, M.D.

      Affiliations

    • Ferring Pharmaceuticals, Inc., Parsippany, New Jersey
    • ,
  • Vladimir I. Yankov, M.D.

      Affiliations

    • Ferring Pharmaceuticals, Inc., Parsippany, New Jersey

Received 11 February 2008 ,Revised 24 March 2008 ,Accepted 24 March 2008.

References 

  1. Daya S. Ovulation induction for corpus luteum deficiency. Semin Reprod Endocrinol. 1990;8:156–165
  2. DiLuigi AJ, Nulsen JC. Effects of gonadotropin-releasing hormone agonists and antagonists on luteal function. Curr Opin Obstet Gynecol. 2007;19:258–265
  3. Smitz J, Devroey P, Camus M, Deschacht J, Khan I, Staessen C, et al. The luteal phase and early pregnancy after combined GnRH-agonist/HMG treatment for superovulation in IVF or GIFT. Hum Reprod. 1988;3:585–590
  4. Vande Wiele RL, Bogumil J, Dyrenfurth I, Ferin M, Jewelewicz R, Warren M, et al. Mechanisms regulating the menstrual cycle in women. Recent Prog Horm Res. 1970;26:63–103
  5. Garcia J, Jones GS, Acosta AA, Wright GL. Corpus luteum function after follicle aspiration for oocyte retrieval. Fertil Steril. 1981;36:565–572
  6. Frydman R, Testart J, Giacomini P, Imbert MC, Martin E, Nahoul K. Hormonal and histological study of the luteal phase in women following aspiration of the preovulatory follicle. Fertil Steril. 1982;38:312–317
  7. Daya S, Gunby J. Luteal phase support in assisted reproduction cycles. Cochrane Database Syst Rev. 2004;CD004830
  8. Nosarka S, Kruger T, Siebert I, Grove D. Luteal phase support in in vitro fertilization: meta-analysis of randomized trials. Gynecol Obstet Invest. 2005;60:67–74
  9. Farhi J, Weissman A, Steinfeld Z, Shorer M, Nahum H, Levran D. Estradiol supplementation during the luteal phase may improve the pregnancy rate in patients undergoing in vitro fertilization-embryo transfer cycles. Fertil Steril. 2000;73:761–766
  10. Gorkemli H, Ak D, Akyurek C, Aktan M, Duman S. Comparison of pregnancy outcomes of progesterone or progesterone + estradiol for luteal phase support in ICSI-ET cycles. Gynecol Obstet Invest. 2004;58:140–144
  11. McAuley JW, Kroboth FJ, Kroboth PD. Oral administration of micronized progesterone: a review and more experience. Pharmacotherapy. 1996;16:453–457
  12. Licciardi FL, Kwiatkowski A, Noyes NL, Berkeley AS, Krey LL, Grifo JA. Oral versus intramuscular progesterone for in vitro fertilization: a prospective randomized study. Fertil Steril. 1999;71:614–618
  13. Miles RA, Paulson RJ, Lobo RA, Press MF, Dahmoush L, Sauer MV. Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes: a comparative study. Fertil Steril. 1994;62:485–490
  14. de Ziegler D. Hormonal control of endometrial receptivity. Hum Reprod. 1995;10:4–7
  15. Levine H, Watson N. Comparison of the pharmacokinetics of crinone 8% administered vaginally versus Prometrium administered orally in postmenopausal women. Fertil Steril. 2000;73:516–521
  16. Pouly JL, Bassil S, Frydman R, Hedon B, Nicollet B, Prada Y, et al. Luteal support after in-vitro fertilization: Crinone 8%, a sustained release vaginal progesterone gel, versus Utrogestan, an oral micronized progesterone. Hum Reprod. 1996;11:2085–2089
  17. Ng EH, Chan CC, Tang OS, Ho PC. A randomized comparison of side effects and patient convenience between Cyclogest suppositories and Endometrin tablets used for luteal phase support in IVF treatment. Eur J Obstet Gynecol Reprod Biol. 2007;131:182–188
  18. Preston R, Norris P, Blake E, Yankov V. Single day and multiple day pharmacokinetics of a novel vaginal micronized progesterone tablet (Endometrin) compared to Crinone vaginal gel in healthy female subjects. Reprod Sci. 2007;14:198A
  19. Doody K, Shamma N, Paulson R, Bayer S, Blake E, Yankov V. Endometrin for luteal phase support in a randomized, controlled, open-label, prospective IVF clinical trial using a combination of Menopur and Bravelle. Fertil Steril. 2007;87:s24
  20. Gibbons WE, Toner JP, Hamacher P, Kolm P. Experience with a novel vaginal progesterone preparation in a donor oocyte program. Fertil Steril. 1998;69:96–101
  21. Chantilis SJ, Zeitoun KM, Patel SI, Johns DA, Madziar VA, McIntire DD. Use of Crinone vaginal progesterone gel for luteal support in in vitro fertilization cycles. Fertil Steril. 1999;72:823–829
  22. Schoolcraft WB, Hesla JS, Gee MJ. Experience with progesterone gel for luteal support in a highly successful IVF programme. Hum Reprod. 2000;15:1284–1288
  23. Yanushpolsky E, Hurwitz S, Greenberg L, Racowsky C, Hornstein MD. Comparison of Crinone 8% intravaginal gel and intramuscular progesterone supplementation for in vitro fertilization/embryo transfer in women under age 40: interim analysis of a prospective randomized trial. Fertil Steril. 2007;89:485–487
  24. Propst AM, Hill JA, Ginsburg ES, Hurwitz S, Politch J, Yanushpolsky EH. A randomized study comparing Crinone 8% and intramuscular progesterone supplementation in in vitro fertilization-embryo transfer cycles. Fertil Steril. 2001;76:1144–1149

 N.K. has nothing to disclose. K.S.R. has nothing to disclose. T.L.N. has nothing to disclose.

 Presented at the 55th Annual Scientific Meeting of the Pacific Coast Reproductive Society, Rancho Mirage, California, April 18–22, 2007.

 Conflict of Interest: the randomized study of different forms of vaginal progesterone supplementation was sponsored by Ferring Pharmaceuticals, Inc. Drs. Blake and Yankov are employees of Ferring Pharmaceuticals, Inc.

PII: S0015-0282(08)00747-4

doi: 10.1016/j.fertnstert.2008.03.072

Fertility and Sterility
Volume 91, Issue 6 , Pages 2445-2450 , June 2009

Article Tools